Doceree's Daily Command — unveiled May 7 in New York, co-built by 75 of the industry's most senior operators — is the answer to a question its founder started asking in a hospital ward. SHORT HILLS, N ...

Pharmaceutical stocks are making a comeback as valuations remain attractive and companies successfully address patent cliff concerns, according to UBS global head of biotech research Michael Yee. In ...

Christine Sloan is an Emmy Award-winning reporter, who covers New Jersey for CBS News New York. Sloan re-joined the station in January 2023. She also worked at CBS News New York from 2004 to 2016.

NEWARK, N.J. — OxyContin maker Purdue Pharma is set to be dissolved and replaced by a company focused on the public good by the week's end, as a massive legal settlement resolving thousands of ...

April 26 (Reuters) - Sun Pharmaceutical Industries (SUN.NS), opens new tab will buy U.S. drugmaker Organon & Co (OGN.N), opens new tab in an all-cash deal valued at about $11.75 billion including debt ...

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

A pharmaceutical company once linked to child deaths due to contaminated cough syrup is now reportedly back in business under a new name—raising serious questions on accountability and regulation.

Despite decades of research showing that traditional interviews are only moderately reliable predictors of performance, organizations continue to rely on them heavily. In fact, the typical interview ...

1. The Secretary of Commerce (Secretary) recently transmitted to me a report on his investigation into the effects of imports of pharmaceuticals and pharmaceutical ingredients on the national security ...

As President Trump’s war in Iran rages on, it’s posing a growing threat to the pharmaceutical supply chain and risks spiking the prices of many drugs, particularly those that depend on petrochemicals.

Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...